Inhibrx Biosciences Files 2024 Proxy Statement
Ticker: INBX · Form: DEF 14A · Filed: Apr 16, 2025 · CIK: 2007919
| Field | Detail |
|---|---|
| Company | Inhibrx Biosciences, Inc. (INBX) |
| Form Type | DEF 14A |
| Filed Date | Apr 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: INBX
TL;DR
INBX proxy filed: exec comp details out, shareholder vote coming.
AI Summary
Inhibrx Biosciences, Inc. filed its DEF 14A proxy statement on April 16, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key individuals mentioned in relation to share-based payment arrangements include Mark P. Lappe, Kelly D. Deck C.P.A., and Brendan P. Eckelman Ph.D., with grants dated May 30, 2024.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation and corporate governance, enabling informed voting decisions on matters presented at the annual meeting.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing providing information to shareholders and does not contain new material financial or operational information that would inherently increase risk.
Key Players & Entities
- Inhibrx Biosciences, Inc. (company) — Filer of the DEF 14A
- Mark P. Lappe (person) — Recipient of share-based payment arrangement option
- Kelly D. Deck C.P.A. (person) — Recipient of share-based payment arrangement option
- Brendan P. Eckelman Ph.D. (person) — Recipient of share-based payment arrangement option
- 2024-12-31 (date) — Fiscal year end
- 20250416 (date) — Filing date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide shareholders with information required for the company's annual meeting, including details on executive compensation, director nominations, and other corporate governance matters.
When is the fiscal year end for Inhibrx Biosciences, Inc. that this filing pertains to?
The fiscal year end for Inhibrx Biosciences, Inc. that this filing pertains to is December 31, 2024.
What is the filing date of this DEF 14A statement?
This DEF 14A statement was filed on April 16, 2025.
Who are some individuals mentioned in relation to share-based payment arrangements?
Individuals mentioned in relation to share-based payment arrangements include Mark P. Lappe, Kelly D. Deck C.P.A., and Brendan P. Eckelman Ph.D.
What was the former name of Inhibrx Biosciences, Inc. and when did the name change occur?
The former name of Inhibrx Biosciences, Inc. was Ibex SpinCo, Inc., and the date of the name change was January 11, 2024.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 16, 2025 by Mark P. Lappe regarding Inhibrx Biosciences, Inc. (INBX).